{"entity":{"id":"paper-intrigue-ripretinib-vs-sunitinib-jco-2022","kind":"paper","name":"INTRIGUE: ripretinib versus sunitinib in advanced gastrointestinal stromal tumour after imatinib","aka":[],"tldr":"Ripretinib was not better than sunitinib as second-line treatment for gastrointestinal stromal tumour overall, but it was better tolerated and worked better in tumours with KIT exon 11 plus exon 17/18 secondary mutations, while sunitinib was better for exon 13/14 mutations.","summary":"Phase 3 open-label trial of 453 patients with advanced GIST after imatinib randomised to ripretinib or sunitinib.\n\nMedian progression-free survival was 8.3 versus 7.0 months in the intention-to-treat population (hazard ratio 0.91, not superior); ripretinib had fewer grade 3 to 4 adverse events (41 versus 66 percent) and better quality of life. Circulating tumour DNA analysis showed ripretinib superior in exon 11 plus 17/18 mutations and sunitinib superior in exon 11 plus 13/14 mutations.","asOf":"2026-09-17","links":[{"label":"J Clin Oncol 2022","url":"https://doi.org/10.1200/JCO.22.00294"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/35947817/"}],"tags":[],"related":[],"cancers":["gist-imatinib-resistant"],"sections":[],"technologies":[],"targets":[],"drugs":["imatinib","ripretinib","sunitinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco"],"dependsOn":[],"notes":[],"journal":"Journal of Clinical Oncology","year":2022,"doi":"10.1200/JCO.22.00294","pmid":"35947817","authors":"Bauer S, Jones RL, Blay JY, et al.","paperType":"rct","findings":["Median progression-free survival 8.3 vs 7.0 months; hazard ratio 0.91 (not superior).","Exon 17/18 secondary mutations: ripretinib 14.2 vs 1.5 months; exon 13/14: sunitinib 15.0 vs 4.0 months."],"whatItMeans":"Sunitinib remains the standard second-line treatment, with ripretinib as a better-tolerated alternative, and mutation-guided choice by circulating tumour DNA is being tested prospectively in INSIGHT.","caveats":["Failed its primary superiority endpoint.","Mutation subgroup analysis was exploratory."],"changedPractice":true,"participants":453},"route":"/key-papers/paper-intrigue-ripretinib-vs-sunitinib-jco-2022/","neighbours":{"cancer":[{"id":"gist-imatinib-resistant","kind":"cancer","name":"Imatinib-resistant GIST","route":"/cancers/gist-imatinib-resistant/"}],"drug":[{"id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/"},{"id":"ripretinib","kind":"drug","name":"Ripretinib","route":"/drugs/ripretinib/"},{"id":"sunitinib","kind":"drug","name":"Sunitinib","route":"/drugs/sunitinib/"}],"journal":[{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/"}]}}